Immuneering Corp
IMRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001790340
No open-market purchases or sales by Immuneering Corp insiders were filed in the last 90 days; 111 institutions reported holding it in 13F filings for Q2 2026, worth $171.6M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +15 vs. previous quarter
- 111
- 13F valueReported value at the end of Q2 2026
- $171.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding IMRX, Q2 2026
No superinvestor reported holding IMRX at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Immuneering Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 24, 2026 (view filing) | Jun 23 | 1 day | Zeskind Benjamin J.PRESIDENT AND CEO | PPurchaseClass A Common Stock | +2.40K | $4.56 | +$10.9K | +0.1%2.32M after | |
| Jun 16, 2026 (view filing) | Jun 15 | 1 day | Hall Brett MatthewCHIEF SCIENTIFIC OFFICER | PPurchaseClass A Common Stock | +6.04K | $4.15 | +$25.0K | +1.6%382.5K after | |
| Jan 21, 2026 (view filing) | Jan 16 | 5 days | Brakewood Harold EugeneChief Business Officer | PPurchaseClass A Common Stock | +5.25K | $4.76 | +$25.0K | +90.5%11.1K after | |
| Jan 20, 2026 (view filing) | Jan 15 | 5 days | Schall Thomas J.Director | PPurchaseClass A Common Stock | +21.6K | $4.67 | +$101.1K | +40.9%74.5K after | |
| Jan 16, 2026 (view filing) | Jan 15 | 1 day | Hall Brett MatthewCHIEF SCIENTIFIC OFFICER | PPurchaseClass A Common Stock | +2.30K | $4.57 | +$10.5K | +0.6%376.5K after | |
| Jan 15, 2026 (view filing) | Jan 13 | 2 days | Neufeld Leah RCHIEF PEOPLE OFFICER | PPurchaseClass A Common Stock | +2.63K | $4.15 | +$10.9K | +11.2%26.0K after | |
| Jan 14, 2026 (view filing) | Jan 12 | 2 days | Feinberg PeterDirector | PPurchaseClass A Common Stock | +20.0K | $4.35 | +$87.0K | +17.3%135.4K after | |
| Oct 7, 2025 (view filing) | Oct 3 | 4 days | Feinberg PeterDirector | PPurchaseClass A Common Stock | +7.50K | $6.67 | +$50.0K | +5.0%156.8K after | |
| Oct 2, 2025 (view filing) | Oct 1 | 1 day | Morales MalloryChief Accounting Officer | PPurchaseClass A Common Stock | +300 | $6.39 | +$1.92K | +1.1%27.5K after | |
| Oct 2, 2025 (view filing) | Oct 1 | 1 day | Neufeld Leah RCHIEF PEOPLE OFFICER | PPurchaseClass A Common Stock | +800 | $6.38 | +$5.10K | +3.5%23.3K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Immuneering Corp at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 9,704,610 | $48.4M | 0.00% | +6,672+0.1% | Added |
| BlackRock, Inc. | 4,374,020 | $21.8M | 0.00% | +2,866,762+190.2% | Added |
| Sanofi | 2,708,559 | $13.5M | 2.53% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 2,286,434 | $11.4M | 0.00% | −1,907−0.1% | Reduced |
| Price T Rowe Associates Inc | 1,936,076 | $9.66M | 0.00% | +106,888+5.8% | Added |
| Geode Capital Management, LLC | 1,370,750 | $6.84M | 0.00% | +732,806+114.9% | Added |
| State Street Corp | 1,001,995 | $5.00M | 0.00% | +733,475+273.2% | Added |
| DCF Advisers, LLC | 790,000 | $3.94M | 1.03% | +648,538+458.5% | Added |
| Marshall Wace, LLP | 731,897 | $3.65M | 0.00% | −1,264,688−63.3% | Reduced |
| Connor, Clark & Lunn Investment Management Ltd. | 601,255 | $3.00M | 0.01% | +200,892+50.2% | Added |